



State of New Jersey
Department of Human Services
Division of Medical Assistance & Health Services

NEWSLETTER

Volume 8 No. 31

June 1998

TO: Physicians, Independent Clinics, and
Certified Nurse Practitioners/Clinical Nurse Specialists - **For Action**
Health Maintenance Organizations - **For Information Only**

SUBJECT: Reimbursement for Rituxan (Rituximab)

EFFECTIVE: Immediately

BACKGROUND: Rituxan (Rituximab) is a new drug approved by the Food and Drug Administration (FDA) as the first engineered monoclonal antibody for the treatment of relapsed or refractory low-grade or follicular, CD20+, B-Cell non-Hodgkin's Lymphoma (NHL). Due to the time period delay between the FDA approval and the CPT-4 designation of a "J" HCPCS code to be used for the billing of this drug, the New Jersey Medicaid and NJ KidCare fee-for-service programs have instituted a temporary billing procedure for the reimbursement of this drug effective immediately and valid for billing until a "J" code has been designated.

ACTION: Effective immediately, the New Jersey Medicaid and NJ KidCare fee-for-service programs will reimburse Physicians, Certified Nurse Practitioners/Clinical Nurse Specialists and Independent Clinics for the use of this drug using the following Level III, HCPCS procedure codes, as described below:

W9346	Rituxan 100 mg vial	\$397.50
W9347	Rituxan 500 mg vial	\$1987.50

NOTE: An office visit (Evaluation and Management (E/M)) procedure code will only be reimbursed by the Division with these codes when there is a separately identifiable E/M service rendered and it is clearly documented in the patient's medical record.

For questions or information regarding this Newsletter, please contact the Division of Medical Assistance and Health Services, Office of Health Service Administration, at (609) 588-2721.

**RETAIN THIS NEWSLETTER NUMERICALLY BEHIND THE NEWSLETTER TAB
(BLUE TAB MARKED "5")**